Global Personalized Medicines Market Size, Status and Forecast 2019-2025

2 Global Personalized Medicines Quarterly Market Size Analysis

• 2.1 Personalized Medicines Business Impact Assessment - COVID-19
  • 2.1.1 Global Personalized Medicines Market Size, Pre-COVID-19 and Post- COVID-19 Comparison, 2015-2026
• 2.2 Global Personalized Medicines Quarterly Market Size 2020-2021
• 2.3 COVID-19-Driven Market Dynamics and Factor Analysis
  • 2.3.1 Drivers
  • 2.3.2 Restraints
  • 2.3.3 Opportunities
  • 2.3.4 Challenges

3 Quarterly Competitive Assessment, 2020

• 3.1 By Players, Global Personalized Medicines Quarterly Market Size, 2019 VS 2020
• 3.2 By Players, Personalized Medicines Headquarters and Area Served
• 3.3 Date of Key Players Enter into Personalized Medicines Market
• 3.4 Key Players Personalized Medicines Product Offered
• 3.5 Mergers & Acquisitions, Expansion Plans

4 Impact of Covid-19 on Personalized Medicines Segments, By Type

• 4.1 Introduction
  • 1.4.1 PM Diagnostics
  • 1.4.2 PM Therapeutics
  • 1.4.3 Personalized Medical Care
  • 1.4.4 Personalized Nutrition & Wellness
• 4.2 By Type, Global Personalized Medicines Market Size, 2019-2021

5 Impact of Covid-19 on Personalized Medicines Segments, By Application

• 5.1 Overview
  • 5.5.1 Hospitals Pharmacies
  • 5.5.2 Retail Pharmacies
  • 5.5.3 Dietary Care Centers
  • 5.5.4 Others
• 5.2 By Application, Global Personalized Medicines Market Size, 2019-2021
  • 5.2.1 By Application, Global Personalized Medicines Market Size by Application, 2019-2021

6 Geographic Analysis

• 6.1 Introduction
• 6.2 North America
  • 6.2.1 Macroeconomic Indicators of US
  • 6.2.2 US
  • 6.2.3 Canada
• 6.3 Europe
  • 6.3.1 Macroeconomic Indicators of Europe
  • 6.3.2 Germany
  • 6.3.3 France
  • 6.3.4 UK
  • 6.3.5 Italy
• 6.4 Asia-Pacific
  • 6.4.1 Macroeconomic Indicators of Asia-Pacific
  • 6.4.2 China
  • 6.4.3 Japan
  • 6.4.4 South Korea
  • 6.4.5 India
  • 6.4.6 ASEAN
• 6.5 Rest of World
  • 6.5.1 Latin America
  • 6.5.2 Middle East and Africa

7 Company Profiles

• 7.1 3G Biotech
  • 7.1.1 3G Biotech Business Overview
  • 7.1.2 3G Biotech Personalized Medicines Quarterly Revenue, 2020
  • 7.1.3 3G Biotech Personalized Medicines Product Introduction
  • 7.1.4 3G Biotech Response to COVID-19 and Related Developments
• 7.2 Quest Diagnostics
  • 7.2.1 Quest Diagnostics Business Overview
  • 7.2.2 Quest Diagnostics Personalized Medicines Quarterly Revenue, 2020
  • 7.2.3 Quest Diagnostics Personalized Medicines Product Introduction
  • 7.2.4 Quest Diagnostics Response to COVID-19 and Related Developments
• 7.3 Laboratory Corporation of America
  • 7.3.1 Laboratory Corporation of America Business Overview
  • 7.3.2 Laboratory Corporation of America Personalized Medicines Quarterly Revenue, 2020
  • 7.3.3 Laboratory Corporation of America Personalized Medicines Product Introduction
  • 7.3.4 Laboratory Corporation of America Response to COVID-19 and Related Developments
• 7.4 Abbott
  • 7.4.1 Abbott Business Overview
  • 7.4.2 Abbott Personalized Medicines Quarterly Revenue, 2020
  • 7.4.3 Abbott Personalized Medicines Product Introduction
  • 7.4.4 Abbott Response to COVID-19 and Related Developments
• 7.5 Agendia NV
  • 7.5.1 Agendia NV Business Overview
  • 7.5.2 Agendia NV Personalized Medicines Quarterly Revenue, 2020
  • 7.5.3 Agendia NV Personalized Medicines Product Introduction
  • 7.5.4 Agendia NV Response to COVID-19 and Related Developments
• 7.6 Asuragen Inc
  • 7.6.1 Asuragen Inc Business Overview
  • 7.6.2 Asuragen Inc Personalized Medicines Quarterly Revenue, 2020
  • 7.6.3 Asuragen Inc Personalized Medicines Product Introduction
  • 7.6.4 Asuragen Inc Response to COVID-19 and Related Developments
• 7.7 Becton Dickinson
  • 7.7.1 Becton Dickinson Business Overview
  • 7.7.2 Becton Dickinson Personalized Medicines Quarterly Revenue, 2020
  • 7.7.3 Becton Dickinson Personalized Medicines Product Introduction
  • 7.7.4 Becton Dickinson Response to COVID-19 and Related Developments
• 7.8 CardioDx Inc.
  • 7.8.1 CardioDx Inc. Business Overview
  • 7.8.2 CardioDx Inc. Personalized Medicines Quarterly Revenue, 2020
  • 7.8.3 CardioDx Inc. Personalized Medicines Product Introduction
  • 7.8.4 CardioDx Inc. Response to COVID-19 and Related Developments
• 7.9 Foundation Medicine
  • 7.9.1 Foundation Medicine Business Overview
  • 7.9.2 Foundation Medicine Personalized Medicines Quarterly Revenue, 2020
  • 7.9.3 Foundation Medicine Personalized Medicines Product Introduction
  • 7.9.4 Foundation Medicine Response to COVID-19 and Related Developments
• 7.10 Qiagen
  • 7.10.1 Qiagen Business Overview
  • 7.10.2 Qiagen Personalized Medicines Quarterly Revenue, 2020
  • 7.10.3 Qiagen Personalized Medicines Product Introduction
  • 7.10.4 Qiagen Response to COVID-19 and Related Developments
• 7.11 Siemens Healthcare
  • 7.11.1 Siemens Healthcare Business Overview
  • 7.11.2 Siemens Healthcare Personalized Medicines Quarterly Revenue, 2020
  • 7.11.3 Siemens Healthcare Personalized Medicines Product Introduction
  • 7.11.4 Siemens Healthcare Response to COVID-19 and Related Developments
• 7.12 Amgen
  • 7.12.1 Amgen Business Overview
  • 7.12.2 Amgen Personalized Medicines Quarterly Revenue, 2020
  • 7.12.3 Amgen Personalized Medicines Product Introduction
  • 7.12.4 Amgen Response to COVID-19 and Related Developments
• 7.13 Bristol-Myers Squibb
  • 7.13.1 Bristol-Myers Squibb Business Overview
  • 7.13.2 Bristol-Myers Squibb Personalized Medicines Quarterly Revenue, 2020
  • 7.13.3 Bristol-Myers Squibb Personalized Medicines Product Introduction
  • 7.13.4 Bristol-Myers Squibb Response to COVID-19 and Related Developments
• 7.14 GE Healthcare
  • 7.14.1 GE Healthcare Business Overview
  • 7.14.2 GE Healthcare Personalized Medicines Quarterly Revenue, 2020
  • 7.14.3 GE Healthcare Personalized Medicines Product Introduction
  • 7.14.4 GE Healthcare Response to COVID-19 and Related Developments
• 7.15 Pfizer
  • 7.15.1 Pfizer Business Overview
  • 7.15.2 Pfizer Personalized Medicines Quarterly Revenue, 2020
  • 7.15.3 Pfizer Personalized Medicines Product Introduction
  • 7.15.4 Pfizer Response to COVID-19 and Related Developments
• 7.16 Sanofi
  • 7.16.1 Sanofi Business Overview
  • 7.16.2 Sanofi Personalized Medicines Quarterly Revenue, 2020
  • 7.16.3 Sanofi Personalized Medicines Product Introduction
  • 7.16.4 Sanofi Response to COVID-19 and Related Developments
• 7.17 23andMe
  • 7.17.1 23andMe Business Overview
  • 7.17.2 23andMe Personalized Medicines Quarterly Revenue, 2020
  • 7.17.3 23andMe Personalized Medicines Product Introduction
  • 7.17.4 23andMe Response to COVID-19 and Related Developments
• 7.18 Illumina
  • 7.18.1 Illumina Business Overview
  • 7.18.2 Illumina Personalized Medicines Quarterly Revenue, 2020
  • 7.18.3 Illumina Personalized Medicines Product Introduction
  • 7.18.4 Illumina Response to COVID-19 and Related Developments

8 Key Findings

9 Appendix

• 9.1 About US